Compare Davita Inc (DVA) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs RLX Technology Inc — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while RLX Technology Inc trades at $1.98 (market cap $2.44B). The key difference: Davita Inc is far larger — about 4.8× RLX Technology Inc's market cap, and RLX Technology Inc pays a 5% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | RLX | |
|---|---|---|
Market Cap | $11.72B | $2.44B |
Sector | Health | Technology |
52-Week High | $240.96 | $2.73 |
52-Week Low | $103.87 | $1.79 |
Enterprise Value | $24.44B | $1.07B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RLX Technology trades at $2.01, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $4.4B with a net profit margin of 22.47%, though it missed EPS estimates for three consecutive quarters. Recent news highlights international expansion, including European integration and a 70% international revenue share.
Outlook is mixed: strong fundamentals with cash flow from operations and no debt support growth, but earnings misses and regulatory risks in the vaping industry pose challenges. The sole analyst coverage recommends Hold, reflecting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
